medmix Balance Sheet Health
Financial Health criteria checks 4/6
medmix has a total shareholder equity of CHF470.5M and total debt of CHF293.7M, which brings its debt-to-equity ratio to 62.4%. Its total assets and total liabilities are CHF1.0B and CHF566.0M respectively. medmix's EBIT is CHF16.6M making its interest coverage ratio 1.6. It has cash and short-term investments of CHF140.7M.
Key information
62.4%
Debt to equity ratio
CHF 293.70m
Debt
| Interest coverage ratio | 1.6x |
| Cash | CHF 140.70m |
| Equity | CHF 470.50m |
| Total liabilities | CHF 566.00m |
| Total assets | CHF 1.04b |
Recent financial health updates
No updates
Recent updates
medmix AG (VTX:MEDX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
Aug 11
medmix (VTX:MEDX) Is Reinvesting At Lower Rates Of Return
Dec 19An Intrinsic Calculation For medmix AG (VTX:MEDX) Suggests It's 21% Undervalued
Oct 27Investors Could Be Concerned With medmix's (VTX:MEDX) Returns On Capital
Aug 16There May Be Reason For Hope In medmix's (VTX:MEDX) Disappointing Earnings
Feb 28medmix (VTX:MEDX) May Have Issues Allocating Its Capital
Jan 14Financial Position Analysis
Short Term Liabilities: MEDX's short term assets (CHF326.4M) exceed its short term liabilities (CHF220.8M).
Long Term Liabilities: MEDX's short term assets (CHF326.4M) do not cover its long term liabilities (CHF345.2M).
Debt to Equity History and Analysis
Debt Level: MEDX's net debt to equity ratio (32.5%) is considered satisfactory.
Reducing Debt: MEDX's debt to equity ratio has reduced from 84.5% to 62.4% over the past 5 years.
Debt Coverage: MEDX's debt is well covered by operating cash flow (23.6%).
Interest Coverage: MEDX's interest payments on its debt are not well covered by EBIT (1.6x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 14:49 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
medmix AG is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christoph Gretler | Credit Suisse |
| Eugen Perger | Research Partners AG |